Braveheart Bio, a biotechnology company focused on developing therapies for hypertrophic cardiomyopathy (HCM) and related cardiovascular conditions, has launched with $185 million in Series A financing. The investment was led by Andreessen Horowitz (a16z Bio + Health), Forbion, OrbiMed, Enavate Sciences, and Frazier Life Sciences.
The company plans to use the funding to accelerate global late-stage clinical development of its lead therapeutic candidate, BHB-1893.
Braveheart Bio’s small molecule candidate, BHB-1893, is a selective cardiac myosin inhibitor designed to improve cardiac function in patients with HCM. The condition is one of the most common rare diseases in the United States, affecting approximately 1 in 500 individuals. HCM results in thickening of the heart muscle and impaired ability to fill and pump blood efficiently. Two-thirds of patients experience obstructive HCM, while the remainder have non-obstructive forms, both presenting significant limitations in daily function and quality of life.
BHB-1893 has already generated clinical data across several studies, including a Phase 2 study in symptomatic obstructive HCM, an ongoing Phase 2 study in non-obstructive HCM, multiple clinical pharmacology studies, and a Phase 3 study in obstructive HCM in China. The company intends to initiate global late-stage development in 2026.
The company’s leadership team includes President and CEO Travis Murdoch, MD, along with senior executives experienced in clinical drug development and company scaling. Industry veteran Chris Viehbacher will chair the Board of Directors. The company’s investor syndicate and board composition reflect a strategic focus on moving BHB-1893 into confirmatory clinical programs.
Early data recently presented at the European Society of Cardiology Congress 2025 indicated that BHB-1893 produced rapid and meaningful reductions in left ventricular outflow tract gradients in obstructive HCM patients, with a dosing profile intended to simplify patient and clinician management. Based on these findings, Braveheart Bio is positioning BHB-1893 to be differentiated in both efficacy and dosing precision compared to existing therapies.
Braveheart Bio’s formation reflects a broader trend of focused investment into therapeutic approaches aimed at disease mechanisms rather than symptom management in cardiovascular conditions, particularly those affecting younger and otherwise active patient populations.
KEY QUOTES:
“Current treatments for HCM leave considerable room for improvement. We see potential for our investigational cardiac myosin inhibitor to be a best-in-class molecule that enhances the efficacy, safety, and convenience of care for patients and prescribers. I am delighted to be leading Braveheart’s highly talented and expanding team, who share a commitment to making a positive impact for patients.”
Travis Murdoch, MD, President and Chief Executive Officer, Braveheart Bio
“We identified BHB-1893 through a global search lasting more than a year for novel, potentially transformative treatments. In our search, BHB-1893 rose to the top, demonstrating significant potential to help patient populations with a clear unmet need.”
Erez Chimovits, MBA, MSc, Board Director, Braveheart Bio
“Braveheart’s leadership team brings a rare combination of cardiovascular drug development expertise and a demonstrated track record of building late-stage companies. Combined with compelling clinical data, Braveheart is well positioned to advance BHB-1893 into late-stage development.”
Jasper Bos, PhD, Board Director, Braveheart Bio
“Braveheart is an exciting company with an excellent team and real potential to make an impact for patients. With a strong leadership team and financial backing, the company is positioned well to advance BHB-1893 with rigor and drive. I am looking forward to contributing in its efforts in my role as Chair.”
Chris Viehbacher, Chair of the Board of Directors, Braveheart Bio
